MBIO News and Press, Mustang Bio Inc. From 04/11/24

2024-04-11 12:24:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. Viking Therapeutics (NASDAQ: VKTX ) is the...

2024-03-28 11:09:29 ET More on Mustang Bio Seeking Alpha’s Quant Rating on Mustang Bio Historical earnings data for Mustang Bio Financial information for Mustang Bio Read the full article on Seeking Alpha For further details see: Mustang Bi...

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong founda...

2024-03-15 17:33:49 ET More on Mustang Bio Seeking Alpha’s Quant Rating on Mustang Bio Historical earnings data for Mustang Bio Financial information for Mustang Bio Read the full article on Seeking Alpha For further details see: Mustang Bi...

2024-03-11 16:56:26 ET More on Mustang Bio Seeking Alpha’s Quant Rating on Mustang Bio Historical earnings data for Mustang Bio Financial information for Mustang Bio Read the full article on Seeking Alpha For further details see: Mustang Bi...

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures fo...

2024-03-08 08:40:50 ET Losers: Amylyx Pharmaceuticals ( AMLX ) -81% as late-stage ALS trial for Relyvrio fails . BigBear.ai Holdings BBAI -20% after Q4 earnings release . AerSale Corp ASLE -20% after Q4 earnings release . OppFi OPFI -17% aft...

2024-03-07 08:57:32 ET DENVER, Colo., Mar 07, 2024 ( 247marketnews.com )- Mustang Bio, Inc. (NASDAQ: MBIO ) reported, this morning, that it published Phase 1 clinical data in Nature Medicine that demonstrated Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) promising safet...

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in median overall survival compared to expected survival rate in cohort with dual intratumoral (I...

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for...